The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Asgard Therapeutics

Asgard Therapetics logo

 

Asgard Therapeutics AB is pioneering the use of cellular reprogramming in cancer immunotherapy. The scientific founders of Asgard have developed a cellular reprogramming technology that forces cancer cells to present their own antigens to the immune system, triggering expansion of cancer cell-specific killer T cells and cancer elimination. Asgard solution is an off-the-shelf cancer immunotherapy that can be administered to multiple patients inducing a personalized immune response. It can be applied to different cancers, representing a platform technology with vast economic potential.

 

Asgard Therapeutics' website

 

 

Asgard Therapeutics

Direct cell reprogramming technologies for cancer immunotherapy.

Founded by Filipe Pereira, Cristiana Pires and Fábio Rosa.

Portfolio company since 2018.

 

Portfolio Manager LU Holding:

christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78

8 Sep 2020